Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial

Richard W Grant, Kelsey E O'Brien, Jessica L Waxler, Jason L Vassy, Linda M Delahanty, Laurie G Bissett, Robert C Green, Katherine G Stember, Candace Guiducci, Elyse R Park, Jose C Florez, James B Meigs, Richard W Grant, Kelsey E O'Brien, Jessica L Waxler, Jason L Vassy, Linda M Delahanty, Laurie G Bissett, Robert C Green, Katherine G Stember, Candace Guiducci, Elyse R Park, Jose C Florez, James B Meigs

Abstract

Objective: To examine whether diabetes genetic risk testing and counseling can improve diabetes prevention behaviors.

Research design and methods: We conducted a randomized trial of diabetes genetic risk counseling among overweight patients at increased phenotypic risk for type 2 diabetes. Participants were randomly allocated to genetic testing versus no testing. Genetic risk was calculated by summing 36 single nucleotide polymorphisms associated with type 2 diabetes. Participants in the top and bottom score quartiles received individual genetic counseling before being enrolled with untested control participants in a 12-week, validated, diabetes prevention program. Middle-risk quartile participants were not studied further. We examined the effect of this genetic counseling intervention on patient self-reported attitudes, program attendance, and weight loss, separately comparing higher-risk and lower-risk result recipients with control participants.

Results: The 108 participants enrolled in the diabetes prevention program included 42 participants at higher diabetes genetic risk, 32 at lower diabetes genetic risk, and 34 untested control subjects. Mean age was 57.9 ± 10.6 years, 61% were men, and average BMI was 34.8 kg/m(2), with no differences among randomization groups. Participants attended 6.8 ± 4.3 group sessions and lost 8.5 ± 10.1 pounds, with 33 of 108 (30.6%) losing ≥5% body weight. There were few statistically significant differences in self-reported motivation, program attendance, or mean weight loss when higher-risk recipients and lower-risk recipients were compared with control subjects (P > 0.05 for all but one comparison).

Conclusions: Diabetes genetic risk counseling with currently available variants does not significantly alter self-reported motivation or prevention program adherence for overweight individuals at risk for diabetes.

Trial registration: ClinicalTrials.gov NCT01034319.

Figures

Figure 1
Figure 1
Proportion of participants attending each week of the 12-week Diabetes Prevention Program.

References

    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235–241
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
    1. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544
    1. Jacobs-van der Bruggen MA, van Baal PH, Hoogenveen RT, et al. Cost-effectiveness of lifestyle modification in diabetic patients. Diabetes Care 2009;32:1453–1458
    1. Herman WH, Hoerger TJ, Brandle M, et al. Diabetes Prevention Program Research Group The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–332
    1. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the diabetes prevention program into the community. The DEPLOY pilot study. Am J Prev Med 2008;35:357–363
    1. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically underserved community: a nonrandomized prospective intervention study. Diabetes Care 2008;31:684–689
    1. Absetz P, Oldenburg B, Hankonen N, et al. Type 2 diabetes prevention in the real world: three-year results of the GOAL Lifestyle Implementation Trial. Diabetes Care 2009;32:1418–1420
    1. Kramer MK, Kriska AM, Venditti EM, et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med 2009;37:505–511
    1. McBride CM, Bowen D, Brody LC, et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med 2010;38:556–565
    1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301–304
    1. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu Rev Public Health 2010;31:89–103
    1. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia 2009;52:2299–2305
    1. Markowitz SM, Park ER, Delahanty LM, O’Brien KE, Grant RW. Perceived impact of diabetes genetic risk testing among patients at high phenotypic risk for type 2 diabetes. Diabetes Care 2011;34:568–573
    1. Marteau TM, French DP, Griffin SJ, et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010:CD007275.
    1. Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics. Deflating the genomic bubble. Science 2011;331:861–862
    1. Grant RW, Meigs JB, Florez JC, et al. Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: the Genetic Counseling/Lifestyle Change (GC/LC) Study for Diabetes Prevention. Clin Trials 2011;8:609–615
    1. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association. National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752
    1. de Miguel-Yanes JM, Shrader P, Pencina MJ, et al. MAGIC Investigators. DIAGRAM+ Investigators Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011;34:121–125
    1. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208–2219
    1. Hivert MF, Grant RW, Shrader P, Meigs JB. Identifying primary care patients at risk for future diabetes and cardiovascular disease using electronic health records. BMC Health Serv Res 2009;9:170.
    1. Waxler JL, O'Brien KE, Delahanty LM, et al. Genetic counseling as a tool for type 2 diabetes prevention: a new genetic counseling framework for common polygenetic disorders. J Genet Couns 2012 Feb 3 [Epub ahead of print]
    1. Greene GW, Rossi SR, Reed GR, Willey C, Prochaska JO. Stages of change for reducing dietary fat to 30% of energy or less. J Am Diet Assoc 1994;94:1105–1110; quiz 1111–1112
    1. Marcus BH, Selby VC, Niaura RS, Rossi JS. Self-efficacy and the stages of exercise behavior change. Res Q Exerc Sport 1992;63:60–66
    1. O’Connell D, Velicer WF. A decisional balance measure and the stages of change model for weight loss. Int J Addict 1988;23:729–750
    1. Lindström J, Ilanne-Parikka P, Peltonen M, et al. Finnish Diabetes Prevention Study Group Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673–1679
    1. Williamson DF, Marrero DG. Scaling up type 2 diabetes prevention programs for high risk persons: progress and challenges in the United States. In Diabetes Prevention in Practice. Schwarz P, Reddy P, Greaves C, Dunbar JA, Schwarz J, Eds. Dresden, TUMAINI Institute for Prevention Management, 2010, p. 69–82
    1. Hivert MF, Jablonski KA, Perreault L, et al. DIAGRAM Consortium. Diabetes Prevention Program Research Group Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes 2011;60:1340–1348
    1. Rosado EL, Bressan J, Martins MF, Cecon PR, Martínez JA. Polymorphism in the PPARgamma2 and beta2-adrenergic genes and diet lipid effects on body composition, energy expenditure and eating behavior of obese women. Appetite 2007;49:635–643
    1. Thanassoulis G, O’Donnell CJ. Mendelian randomization: nature’s randomized trial in the post-genome era. JAMA 2009;301:2386–2388
    1. Collins F. Has the revolution arrived? Nature 2010;464:674–675
    1. Green RC, Roberts JS, Cupples LA, et al. REVEAL Study Group Disclosure of APOE genotype for risk of Alzheimer’s disease. N Engl J Med 2009;361:245–254
    1. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008;299:1320–1334
    1. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011;364:524–534
    1. Verrilli DW, Welch HG. The impact of diagnostic testing on therapeutic interventions. JAMA 1996;275:1189–1191
    1. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011;364:1144–1153

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅